3 years ago
Oxford-Astrazenece vaccine used against covid so far in Nepal has been proven safe and effective in the long-awaited US trial.
Vaccine was tested on more than 32,000 volunteers in the United States, Chile and Peru. Vaccines have been found to be 79 percent effective in preventing symptomatic colic and 100 percent effective in preventing serious illness. And the results of the test have shown that there is no risk of blood clots.
The results are expected to allay concerns about the blood clots in European countries that have recently suspended vaccination program. Some countries have resumed suspended vaccination programs after European drug regulators reviewed them and said they were safe and effective.
New tests from Columbia University and University of Rochester show that the vaccine is more reliable and can be used in people over 65 years of age. Some countries initially did not vaccinate people over the age of 65 because of lack of data.
But 20 percent of the participants in the US trial were over 65 years of age who were given the same protection as young people with two doses of the four-week vaccine.
Millions of people have been vaccinated in other countries, so the number of participants in the test is not very large.
But this result was necessary for the vaccine to be approved in the United States. Vaccine is expected to be approved in the next one to two months.
Professor Andrew Pollard, lead researcher on vaccine testing at Oxford University, said: "This result demonstrates the effectiveness of vaccines in new populations and is in line with our test results.
